Quantitative Systems Pharmacology plays a critical role in improving target selection and validation by integrating biological knowledge with computational modeling to enhance drug discovery success.
Target selection and validation involves identifying and validating a biological target that is involved in the disease process and that can be modulated by a drug to produce a therapeutic benefit.
By carefully selecting and validating a target, drug developers can increase the chances of success in developing a new drug. Once a target has been validated, it can be used to design and develop drugs that interact with that target and modulate its function.
Significance of target selection and validation
The success of any drug majorly depends on its ability to aim for “the right target,” which increases the drug’s efficacy. This is possible when researchers have an adequate understanding of disease biology.
Insufficient knowledge or failure at this stage would result in poor target choice and incorrect biomarker identification, hampering patient selection during clinical trials.
This can lead to significant loss of time, delays in drug development, and financial losses.
Therefore, target selection and validation are critical steps in the drug development process. The process involves identifying a molecular target or pathway involved in a particular disease and testing the target’s suitability for drug development.
Target selection involves identifying a specific biological target, such as a protein or enzyme, that plays an essential role in the disease process and has a known mechanism of action.
The role of quantitative systems pharmacology in drug discovery
Target identification and validation is an area where quantitative systems pharmacology can play a crucial role in strengthening the drug discovery and development process.
Quantitative Systems Pharmacology is a modeling approach that integrates quantitative information about drug properties, pharmacokinetics, and pharmacodynamics to develop mechanistic models of drug action in biological systems.
One of the key benefits of quantitative systems pharmacology is its ability to incorporate data from multiple sources, including preclinical studies, clinical trials, and real-world data.
By simulating the behavior of a drug in the body, QSP models can identify potential targets, predict the effects of different doses and regimens, and optimize the design of clinical trials.
QSP also helps improve target validation by providing a more detailed understanding of the biological mechanisms involved in disease and drug action.
These insights are often supported by bioinformatics services and integrated scientific informatics platforms.
Use of QSP models in target validation
QSP models simulate complex interactions between drugs and their targets, as well as the effects of drugs on physiological systems.
These models provide insights into mechanisms of action and help identify promising drug targets based on their potential to modulate disease-relevant pathways.
Furthermore, quantitative systems pharmacology can be used to optimize the selection of preclinical models.
By predicting pharmacokinetics and pharmacodynamics across species, QSP informs decisions about appropriate experimental systems for drug development.
For example, QSP models played a role in validating the target of the drug Gleevec for the treatment of chronic myeloid leukemia.
QSP in clinical trial design
Quantitative systems pharmacology supports clinical trial design by predicting the effects of different dosing regimens and patient populations on drug efficacy and safety.
QSP models also assist in identifying biomarkers to monitor drug response during clinical trials, accelerating development by providing early evidence of efficacy.
This approach aligns closely with clinical data services and data-driven drug discovery initiatives.
Why choose excelra for quantitative systems pharmacology?
At Excelra, we have a robust and refined approach to collecting, aggregating, and processing pharmacological data.
Our expertise spans the entire drug discovery and development lifecycle, from target identification and validation to clinical trials and post-market monitoring.
We support quantitative systems pharmacology teams directly by delivering indication-specific clinical, preclinical, and biomarker datasets for disease modeling.
Our standardized, analysis-ready datasets include pharmacokinetic (PK), pharmacodynamic (PD), toxicology, and clinical endpoint data.
Excelra has delivered clinical trial outcomes datasets across more than 130 indications, processing data from over 30,000 clinical trials.
These capabilities are strengthened by scientific data management and data curation services.
Speed your drug discovery process with expert support in target selection and validation using Quantitative Systems Pharmacology.
